Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
75.00 USD   -0.70%
11/23Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
BU
11/17Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Novocure to Participate in Upcoming Investor Conferences

08/31/2022 | 08:01am EST

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

Ms. Cordova will be joined by Dr. Ely Benaim, Chief Medical Officer, for additional one-on-one meetings with investors as part of the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022.

Novocure’s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 24, 2022, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.


ę Business Wire 2022
All news about NOVOCURE LIMITED
11/23Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
BU
11/17Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-O..
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
BU
11/15Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
CI
11/14Novocure Secures CE Mark for New Array
AQ
11/11NovoCure Says it Will Initiate Limited Market Release of Transducer Array in Europe Aft..
MT
11/11Novocure Secures CE Mark for New Array
BU
11/04Novocure Ltd : Other Events (form 8-K)
AQ
10/28Wells Fargo Adjusts Price Target on NovoCure to $74 From $70, Keeps Equal Weight Rating
MT
10/28Truist Securities Trims NovoCure's Price Target to $102 From $105, Maintains Buy Rating
MT
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 538 M - -
Net income 2022 -83,2 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -92,6x
Yield 2022 -
Capitalization 7 871 M 7 871 M -
EV / Sales 2022 14,8x
EV / Sales 2023 14,3x
Nbr of Employees 1 167
Free-Float 98,9%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 75,00 $
Average target price 89,38 $
Spread / Average Target 19,2%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED-0.11%7 871
SHOCKWAVE MEDICAL, INC.48.19%9 551
MASIMO CORPORATION-50.53%7 614
PENUMBRA, INC.-31.80%7 442
GETINGE AB-41.53%6 033
ASAHI INTECC CO., LTD.5.14%5 069